Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic

Critical Reviews in Oncology/Hematology

Volumn 61, Issue 1, 2007, Pages 52-69

  de Groot, D J A ^a   de Vries, E G E ^a   Groen, H J M ^a   de Jong, S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chemotherapy; Cyclooxygenase; NSAIDs

Indexed keywords

1 [BETA DEXTRO ARABINOFURANOSYL]CYTOSINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOSINE DERIVATIVE; DICLOFENAC; DOXORUBICIN; ETODOLAC; IBUPROFEN; INDOMETACIN; IRINOTECAN; MELOXICAM; METHOTREXATE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PIROXICAM; ROFECOXIB; SULINDAC SULFIDE; TILMACOXIB; UNINDEXED DRUG; VALDECOXIB; VINCRISTINE;

ADENOMA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; DUODENUM INJURY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; INTESTINE CANCER; KNOCKOUT MOUSE; LIVER CANCER; MELANOMA; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PANCREAS CANCER; PEPTIC ULCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STOMACH CANCER; STOMACH MUCOSA INJURY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; XENOGRAFT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS;

EID: 33845344739     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.07.001     Document Type: Review

References (217)

1. Imperiale T.F. Aspirin and the prevention of colorectal cancer. N Engl J Med 348 (2003) 879-880
2. Koehne C.H., and DuBois R.N. COX-2 inhibition and colorectal cancer. Semin Oncol 31 (2004) 12-21
3. Khuder S.A., and Mutgi A.B. Breast cancer and NSAIDs use: a metaanalysis. Br J Cancer 84 (2001) 1188-1192
4. Castelao J.E., Yuan J.M., Gago-Dominguez M., Yu M.C., and Ross R.K. Non steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82 (2000) 1364-1369
5. Irani J., Ravery V., Pariente J.L., et al. Effect of non steroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 168 (2002) 1985-1988
6. Harris R.E., Beebe-Donk J., and Schuller H.M. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 9 (2002) 693-695
7. Muscat J.E., Chen S.Q., Richie Jr. J.P., et al. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer 97 (2003) 1732-1736
8. Lands W.E. The biosynthesis and metabolism of prostaglandins. Annu Rev Physiol 41 (1979) 633-652
9. Merlie J.P., Fagan D., Mudd J., and Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 263 (1988) 3550-3553
10. DeWitt D.L., and Smith W.L. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85 (1988) 1412-1416
11. Yokoyama C., Takai T., and Tanabe T. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett 231 (1988) 347-351
12. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., and Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88 (1991) 2692-2696
13. Chandrasekharan N.V., Dai H., Roos K.L., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 15 99 (2002) 13926-13931
14. Josephy P.D., Chiu A.L., and Eling T.E. Prostaglandin H synthase-dependent mutagenic activation of benzidine in a Salmonella typhimurium Ames tester strain possessing elevated N-acetyltransferase levels. Cancer Res 15 49 (1989) 853-856
15. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
16. Herschman H.R. Prostaglandin synthase 2. Biochim Biophys Acta 5 1299 (1996) 125-140
17. Dubois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998) 1063-1073
18. Herschman H.R., Xie W., and Reddy S. Inflammation, reproduction, cancer and all that .... The regulation and role of the inducible prostaglandin synthase. Bioessays 17 (1995) 1031-1037
19. Kage K., Fujita N., Oh-hara T., Ogata E., Fujita T., and Tsuruo T. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem Biophys Res Commun 254 (1999) 259-263
20. Fong C.Y., Pang L., Holland E., and Knox A.J. TGF-beta1 stimulates IL-8 release, COX-2 expression, and PGE(2) release in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 279 (2000) L201-L207
21. Saha D., Datta P.K., Sheng H., et al. Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1 (1999) 508-517
22. Diaz A., Chepenik K.P., Korn J.H., Reginato A.M., and Jimenez S.A. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241 (1998) 222-229
23. Kosaka T., Miyata A., Ihara H., et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 221 (1994) 889-897
24. Tanabe T., and Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68-69 (2002) 95-114
25. Iniguez M.A., Martinez-Martinez S., Punzon C., Redondo J.M., and Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275 (2000) 23627-23635
26. Liu Y., Borchert G.L., and Phang J.M. Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells. J Biol Chem 279 (2004) 18694-18700
27. Miller C., Zhang M., He Y., et al. Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: co-stimulation of AP-1 and CRE nuclear binding proteins. J Cell Biochem 69 (1998) 392-413
28. Morham S.G., Langenbach R., Loftin C.D., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83 (1995) 473-482
29. Bombardier C., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
30. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
31. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
32. Bjorkman D.J. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 105 (1998) 8S-12S
33. Kato M., Nishida S., Kitasato H., Sakata N., and Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 53 (2001) 1679-1685
34. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96 (1999) 7563-7568
35. Patrignani P., Panara M.R., Sciulli M.G., Santini G., Renda G., and Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48 (1997) 623-631
36. Arico S., Pattingre S., Bauvy C., et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277 (2002) 27613-27621
37. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2 (2001) 544-551
38. Wang D., and Dubois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
39. Hull M.A. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?. Eur J Cancer 41 (2005) 1854-1863
40. Oshima M., Oshima H., Kitagawa K., Kobayashi M., Itakura C., and Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 92 (1995) 4482-4486
41. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Apc delta716 knock-out mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
42. Moser A.R., Pitot H.C., and Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 (1990) 322-324
43. Shoemaker A.R., Gould K.A., Luongo C., Moser A.R., and Dove W.F. Studies of neoplasia in the Min mouse. Biochim Biophys Acta 1332 (1997) F25-F48
44. Chulada P.C., Thompson M.B., Mahler J.F., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60 (2000) 4705-4708
45. Liu C.H., Chang S.H., Narko K., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276 (2001) 18563-18569
46. Seed M.P., Brown J.R., Freemantle C.N., et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 57 (1997) 1625-1629
47. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
48. Kuwashima L., Graeber J., and Glaser B.M. Stimulation of endothelial cell prostacyclin release by retina-derived factors. Invest Ophthalmol Vis Sci 29 (1988) 1213-1220
49. Murohara T., Horowitz J.R., Silver M., et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97 (1998) 99-107
50. Liu X.H., Kirschenbaum A., Lu M., et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277 (2002) 50081-50086
51. Krysan K., Reckamp K.L., Dalwadi H., et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65 (2005) 6275-6281
52. Cheng T., Cao W., Wen R., Steinberg R.H., and LaVail M.M. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 39 (1998) 581-591
53. Amano H., Hayashi I., Endo H., et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197 (2003) 221-232
54. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
55. Williams C.S., Tsujii M., Reese J., Dey S.K., and DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105 (2000) 1589-1594
56. Lim S.C. Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. Oncol Rep 10 (2003) 1241-1249
57. Timoshenko A.V., Chakraborty C., Wagner G.F., and Lala P.K. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 94 8 (2006) 1154-1163
58. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
59. Brueggemeier R.W., Quinn A.L., Parrett M.L., Joarder F.S., Harris R.E., and Robertson F.M. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140 (1999) 27-35
60. Karuppu D., Kalus A., Simpson E.R., and Clyne C. Aromatase and prostaglandin inter-relationships in breast adipose tissue: significance for breast cancer development. Breast Cancer Res Treat 76 (2002) 103-109
61. Sheng H., Shao J., Washington M.K., and DuBois R.N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276 (2001) 18075-18081
62. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94 (1997) 3336-3340
63. Singh B., Berry J.A., Shoher A., Ramakrishnan V., and Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26 (2005) 1393-1399
64. Davis T.W., O'Neal J.M., Pagel M.D., et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 64 (2004) 279-285
65. Terakado N., Shintani S., Yano J., et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol 40 (2004) 383-389
66. Shin Y.K., Park J.S., Kim H.S., et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65 (2005) 9501-9509
67. Reed J.C. Dysregulation of apoptosis in cancer. J Clin Oncol 17 (1999) 2941-2953
68. Campos L., Rouault J.P., Sabido O., et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81 (1993) 3091-3096
69. Bargou R.C., Daniel P.T., Mapara M.Y., et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60 (1995) 854-859
70. Prokop A., Wieder T., Sturm I., et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14 (2000) 1606-1613
71. Sturm I., Kohne C.H., Wol G., et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17 (1999) 1364-1374
72. Lima R.T., Martins L.M., Guimaraes J.E., Sambade C., and Vasconcelos M.H. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11 (2004) 309-316
73. Zangemeister-Wittke U. Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling. Ann N Y Acad Sci 1002 (2003) 90-94
74. Nita M.E., Nagawa H., Tominaga O., et al. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 78 (1998) 986-992
75. Liu X.H., Yao S., Kirschenbaum A., and Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58 (1998) 4245-4249
76. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
77. Zhou X.M., Wong B.C., Fan X.M., et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 22 (2001) 1393-1397
78. Ding H., Han C., Zhu J., Chen C.S., and D'Ambrosio S.M. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113 (2005) 803-810
79. Narayanan B.A., Condon M.S., Bosland M.C., Narayanan N.K., and Reddy B.S. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 9 (2003) 3503-3513
80. Gajewski T.F., and Thompson C.B. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 87 (1996) 589-592
81. Cardone M.H., Roy N., Stennicke H.R., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
82. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275 (2000) 11397-11403
83. Basu G.D., Pathangey L.B., Tinder T.L., Lagioia M., Gendler S.J., and Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2 (2004) 632-642
84. Zhang Z., Lai G.H., and Sirica A.E. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39 (2004) 1028-1037
85. Wu T., Leng J., Han C., and Demetris A.J. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3 (2004) 299-307
86. Lin M.T., Lee R.C., Yang P.C., Ho F.M., and Kuo M.L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 276 (2001) 48997-49002
87. Adida C., Recher C., Raffoux E., et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111 (2000) 196-203
88. Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., and Altieri D.C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351 (1998) 882-883
89. Li J., Feng Q., Kim J.M., et al. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142 (2001) 370-380
90. Datta R., Oki E., Endo K., Biedermann V., Ren J., and Kufe D. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem 275 (2000) 31733-31738
91. Nishihara H., Kizaka-Kondoh S., Insel P.A., and Eckmann L. Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 100 (2003) 8921-8926
92. Krysan K., Merchant F.H., Zhu L., et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18 (2004) 206-208
93. Krysan K., Dalwadi H., Sharma S., Pold M., and Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64 (2004) 6359-6362
94. Zhang T., Fields J.Z., Ehrlich S.M., and Boman B.M. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308 (2004) 434-437
95. Shishodia S., and Aggarwal B.B. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 279 (2004) 47148-47158
96. Wang C.Y., Cusack Jr. J.C., Liu R., and Baldwin Jr. A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5 (1999) 412-417
97. Guo J., Verma U.N., Gaynor R.B., Frenkel E.P., and Becerra C.R. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 10 (2004) 3333-3341
98. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994) 956-959
99. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
100. Yamamoto Y., Yin M.J., Lin K.M., and Gaynor R.B. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274 (1999) 27307-27314
101. Wong B.C., Jiang X., Fan X.M., et al. Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 22 (2003) 1189-1197
102. Shishodia S., Koul D., and Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173 (2004) 2011-2022
103. Duffy C.P., Elliott C.J., O'Connor R.A., et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34 (1998) 1250-1259
104. Kang H.K., Lee E., Pyo H., and Lim S.J. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 4 (2005) 1358-1363
105. Puhlmann U., Ziemann C., Ruedell G., et al. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 312 (2005) 346-354
106. O'Connor R., Heenan M., Connolly L., Larkin A., and Clynes M. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24 (2004) 457-464
107. Mizutani Y., Nakanishi H., Li Y.N., Sato N., Kawauchi A., and Miki T. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J Urol 172 (2004) 1474-1479
108. Lin J., Hsiao P.W., Chiu T.H., and Chao J.I. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 70 (2005) 658-667
109. Czembirek C., Eder-Czembirek C., Erovic B.M., Turhani D., Selzer E., and Thurnher D. Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines. Oncol Rep 14 (2005) 1523-1526
110. Vadlamudi R., Mandal M., Adam L., Steinbach G., Mendelsohn J., and Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18 (1999) 305-314
111. Subbaramaiah K., Norton L., Gerald W., and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277 (2000) 18649-18657
112. Wang S.C., Lien H.C., Xia W., et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6 (2004) 251-261
113. Mann M., Sheng H., Shao J., et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120 (2001) 1713-1719
114. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
115. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4 (2001) S3-S8
116. Buchanan F.G., Wang D., Bargiacchi F., and DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278 (2003) 35451-35457
117. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., and Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 (2002) 289-293
118. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., and DuBois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23 (2005) 254-266
119. Shao J., Lee S.B., Guo H., Evers B.M., and Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63 (2003) 5218-5223
120. Özören N., and El-Deiry W.S. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 13 (2003) 135-147
121. de Jong S., Timmer T., Heijenbrok F.J., and de Vries E.G.E. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 20 (2001) 51-56
122. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
123. Zhang Z., Lai G.H., and Sirica A.E. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39 (2004) 1028-1037
124. Han Z., Pantazis P., Wyche J.H., Kouttab N., Kidd V.J., and Hendrickson E.A. A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line. J Biol Chem 276 (2001) 38748-38754
125. de Groot D.J., Timmer T., Spierings D.C., Le T.K., de Jong S., and de Vries E.G. Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells. Br J Cancer 92 (2005) 1459-1466
126. Cheng A.S., Chan H.L., Leung W.K., Wong N., Johnson P.J., and Sung J.J. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Oncol 23 (2003) 113-119
127. Liu X., Yue P., Zhou Z., Khuri F.R., and Sun S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96 (2004) 1769-1780
128. Huang Y., He Q., Hillman M.J., Rong R., and Sheikh M.S. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 61 (2001) 6918-6924
129. Martin S., Phillips D.C., Szekely-Szucs K., Elghazi L., Desmots F., and Houghton J.A. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 65 (2005) 11447-11458
130. He Q., Luo X., Huang Y., and Sheikh M.S. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 21 (2002) 6032-6040
131. Huang Y., He Q., Hillman M.J., Rong R., and Sheikh M.S. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 61 (2001) 6918-6924
132. Tang X., Sun Y.J., Half E., Kuo M.T., and Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62 (2002) 4903-4908
133. Ravi R., and Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res 62 (2002) 1583-1587
134. Teicher B.A., Korbut T.T., Menon K., Holden S.A., and Ara G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol 33 (1994) 515-522
135. Hattori K., Matsushita R., Kimura K., Abe Y., and Nakashima E. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. Biol Pharm Bull 24 (2001) 1214-1217
136. Matsushita R., Hattori K., Hayashi K., Iizasa H., Ichimura F., and Nakashima E. Synergistic effect of indomethacin and bleomycin on tumor growth produced by activating antitumor immunity. Pharm Res 18 (2001) 243-245
137. Yao M., Kargman S., Lam E.C., et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63 (2003) 586-592
138. Lala P.K., Elkashab M., Kerbel R.S., and Parhar R.S. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ. Int Immunol 2 (1990) 1149-1158
139. Knapp D.W., Glickman N.W., Widmer W.R., et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 46 (2000) 221-226
140. Hayashi N., Yamamoto H., Hiraoka N., et al. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 34 (2001) 638-660
141. Howe L.R., Subbaramaiah K., Brown A.M., and Dannenberg A.J. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8 (2001) 97-114
142. Kagoura M., Toyoda M., Matsui C., and Morohashi M. Immunohistochemical expression of cyclooxygenase-2 in skin cancers. J Cutan Pathol 28 (2001) 298-302
143. Kulkarni S., Rader J.S., Zhang F., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7 (2001) 429-434
144. Marrogi A., Pass H.I., Khan M., Metheny-Barlow L.J., Harris C.C., and Gerwin B.I. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 60 (2000) 3696-3700
145. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59 (1999) 991-994
146. Shiota G., Okubo M., Noumi T., et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46 (1999) 407-412
147. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., and Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58 (1998) 4997-5001
148. Tucker O.N., Dannenberg A.J., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59 (1999) 987-990
149. Uefuji K., Ichikura T., and Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 76 (2001) 26-30
150. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., and Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59 (1999) 198-204
151. Kondo M., Yamamoto H., Nagano H., et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 5 (1999) 4005-4012
152. Mohammed S.I., Knapp D.W., Bostwick D.G., et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59 (1999) 5647-5650
153. Tong B.J., Tan J., Tajeda L., et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2 (2000) 483-490
154. Muller-Decker K., Reinerth G., Krieg P., et al. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 82 (1999) 648-656
155. Yoshimura R., Sano H., Masuda C., et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89 (2000) 589-596
156. Fujita T., Matsui M., Takaku K., et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58 (1998) 4823-4826
157. Sheehan K.M., Sheahan K., O'Donoghue D.P., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282 (1999) 1254-1257
158. Koki A.T., and Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Contr 9 (2002) 28-35
159. Shirahama T., Arima J., Akiba S., and Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92 (2001) 188-193
160. Achiwa H., Yatabe Y., Hida T., et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5 (1999) 1001-1005
161. Khuri F.R., Wu H., Lee J.J., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7 (2001) 861-867
162. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
163. Takahashi T., Kozaki K., Yatabe Y., Achiwa H., and Hida T. Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol 21 (2002) 177-181
164. Hase T., Yoshimura R., Matsuyama M., et al. Cyclooxygenase-1 and -2 in human testicular tumours. Eur J Cancer 39 (2003) 2043-2049
165. Morris C.D., Armstrong G.R., Bigley G., Green H., and Attwood S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96 (2001) 990-996
166. Wilson K.T., Fu S., Ramanujam K.S., and Meltzer S.J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58 (1998) 2929-2934
167. Saukkonen K., Rintahaka J., Sivula A., et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 111 (2003) 915-925
168. Sung J.J., Leung W.K., Go M.Y., et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 157 (2000) 729-735
169. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6 (2000) 2424-2430
170. Buckman S.Y., Gresham A., Hale P., et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19 (1998) 723-729
171. Hosomi Y., Yokose T., Hirose Y., et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30 (2000) 73-81
172. Ohno R., Yoshingaga K., Fujita T., et al. Depth of invasison parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 91 (2001) 1876-1881
173. Murata H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 94 (1999) 451-455
174. Lim H.Y., Joo H.J., Choi J.H., et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 6 (2000) 519-525
175. Fujita T., Matsui M., Takaku K., et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58 (1998) 4823-4826
176. Sheehan K.M., Sheahan K., O'Donoghue D.P., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282 (1999) 1254-1257
177. Chen W.S., Wei S.J., Liu J.M., Hsiao M., Kou-Lin J., and Yang W.K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91 (2001) 894-899
178. Denkert C., Winzer K.J., Muller B.M., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97 (2003) 2978-2987
179. Ristimaki A., Sivula A., Lundin J., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62 (2002) 632-635
180. Wulfing P., Diallo R., Muller C., et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129 (2003) 375-382
181. Yuan A., Yu C.J., Shun C.T., et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 115 (2005) 545-555
182. Kim H.S., Youm H.R., Lee J.S., Min K.W., Chung J.H., and Park C.S. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 42 (2003) 163-170
183. Ferrandina G., Ranelletti F.O., Legge F., et al. Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer. Clin Cancer Res 10 (2004) 3117-3123
184. Chen Y.J., Wang L.S., Wang P.H., et al. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol Oncol 88 (2003) 379-385
185. Erkinheimo T.L., Lassus H., Finne P., et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 10 (2004) 538-545
186. Gallo O., Masini E., Bianchi B., Bruschini L., Paglierani M., and Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 33 (2002) 708-714
187. Ranelletti F.O., Almadori G., Rocca B., et al. Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 95 (2001) 343-349
188. Wulfing C., Eltze E., von Struensee D., Wulfing P., Hertle L., and Piechota H. Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol 45 (2004) 46-52
189. Kim S.I., Kwon S.M., Kim Y.S., and Hong S.J. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 60 (2002) 816-821
190. Soumaoro L.T., Uetake H., Higuchi T., Takagi Y., Enomoto M., and Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10 (2004) 8465-8471
191. Hull M.A., Fenwick S.W., Chapple K.S., Scott N., Toogood G.J., and Lodge J.P. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 18 (2000) 21-27
192. Baldi A., Santini D., Vasaturo F., et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 59 (2004) 428-433
193. Edwards J.G., Faux S.P., Plummer S.M., et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 8 (2002) 1857-1862
194. Buskens C.J., Van Rees B.P., Sivula A., et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122 (2002) 1800-1807
195. Okano H., Shinohara H., Miyamoto A., Takaori K., and Tanigawa N. Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome. Clin Cancer Res 10 (2004) 6938-6945
196. Phillips R.K., et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50 (2002) 857-860
197. Lundholm K., Gelin J., Hyltander A., et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54 (1994) 5602-5606
198. Pruthi R.S., Derksen J.E., and Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 93 (2004) 275-278
199. Ferrandina G., Ranelletti F.O., Legge F., et al. Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 9 (2003) 4324-4331
200. Fenwick S.W., Toogood G.J., Lodge J.P., and Hull M.A. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125 (2003) 716-729
201. Arber N. Chemoprevention of colorectal adenomas with celecoxib in an international randomized, placebo-controlled, double-blind trial. American Association for Cancer Research, abstract number CP-4; 2006.
202. Bertagnolli MM, Eagle CJ, Hawk ET, The Adenoma Prevention with Celecoxib (APC) Study. Celecoxib reduces sporadic colorectal adenomas: results from the Adenoma Prevention with Celecoxib (APC) trial. American Association for Cancer Research, abstract number CP-3; 2006.
203. Lin E., Morris J.S., and Ayers G.D. Effect of celecoxib on capecitabine induced hand-foot syndrome and antitumor activity. Oncology (Huntingt) 16 (2002) 31-37
204. Kobayashi S., Okada S., Hasumi T., Sato N., and Fujimura S. The marked anticancer effect of combined VCR, MTX, and indomethacin against drug-resistant recurrent small cell lung carcinoma after conventional chemotherapy: report of a case. Surg Today 29 (1999) 666-669
205. Altorki N.K., Keresztes R.S., Port J.L., et al. Celecoxib a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21 (2003) 2645-2650
206. Chow L.W., Wong J.L., and Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 86 (2003) 443-447
207. Dang C.T., Dannenberg A.J., Subbaramaiah K., et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 10 (2004) 4062-4067
208. Becerra C.R., Frenkel E.P., Ashfaq R., and Gaynor R.B. Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer 105 (2003) 868-872
209. Spieth K., Kaufmann R., and Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 52 (2003) 377-382
210. Kohne C., De Greve J., Bokemeyer C., et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. J Clin Oncol 23 Suppl 16 (2005) A-3252-A-3525
211. Lin E., Morris J.S., and Ayers G.D. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 16 (2002) 31-37
212. Trifan O.C., Durham W.F., Salazar V.S., et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62 (2002) 5778-5784
213. Gambaro G., and Perazella M.A. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 253 (2003) 643-652
214. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606
215. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
216. Bresalier R.S., Sandler R.S., Quan H., et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
217. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080